Enlicitide Decanoate: Risks & Legal Status

Critical Safety Information#

Enlicitide decanoate (MK-0616) is an investigational medication that has not been approved by any regulatory authority worldwide. All information presented here is derived from published clinical trial data and company press releases. This content is for educational and research reference purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Safety Profile#

Clinical Trial Safety Data#

Across the CORALreef Phase 3 program, enlicitide has demonstrated a safety profile comparable to placebo:

• Overall adverse events: 64% enlicitide vs 62% placebo (CORALreef HeFH)
• Serious adverse events: 10% enlicitide vs 12% placebo (CORALreef HeFH)
• Discontinuation due to AEs: 3.1% enlicitide vs 4.1% placebo (CORALreef Lipids)
• No excess in any specific adverse event category
• No injection site reactions (oral administration)

Class Safety of PCSK9 Inhibition#

The PCSK9 inhibitor class has an established long-term safety record from injectable antibodies:

• FOURIER (evolocumab): No excess adverse events over median 2.2 years
• ODYSSEY OUTCOMES (alirocumab): No excess adverse events over median 2.8 years
• No confirmed neurocognitive effects in dedicated studies (EBBINGHAUS)
• No excess diabetes risk above that associated with LDL lowering per se

This class-level safety evidence provides reassurance about the target biology, though enlicitide's oral macrocyclic peptide platform represents a novel molecular format.

Risk-Benefit Analysis#

Potential Benefits#

• First oral PCSK9 inhibitor, potentially improving access and adherence
• LDL-C reduction (55-60%) matching injectable PCSK9 antibodies
• Broad lipid effects (apoB, non-HDL-C, Lp(a) reductions)
• No injection burden, cold chain, or injection training required
• Safety profile comparable to placebo through 52 weeks
• Complementary mechanism to statins (blocks compensatory PCSK9 upregulation)

Potential Risks#

• Cardiovascular outcomes not proven: LDL-C reduction is a well-validated surrogate, but enlicitide has not yet demonstrated reduced cardiovascular events in a dedicated outcomes trial
• Unknown long-term effects: Data limited to 52 weeks of continuous treatment
• Daily adherence requirement: Unlike biweekly/monthly injectable PCSK9 inhibitors, enlicitide requires daily dosing, which may present adherence challenges for some patients
• Novel molecular platform: While PCSK9 inhibition is well-characterized, the macrocyclic peptide format is a novel drug modality with limited post-marketing precedent

Risk Mitigation#

• Cardiovascular risk monitoring through standard lipid panels
• Liver function monitoring per standard lipid therapy guidelines
• Ongoing CORALreef Outcomes trial (19,000+ participants) will provide definitive outcomes data
• Integration with existing cardiovascular risk management programs

Regulatory Status#

United States#

Merck expects to submit enlicitide for FDA approval in early 2026, based on the CORALreef Phase 3 program. The FDA may consider LDL-C reduction as a basis for accelerated or standard approval, with cardiovascular outcomes data from CORALreef Outcomes potentially required as a post-marketing commitment.

European Union#

Regulatory submissions in Europe are anticipated following the US filing but have not been formally announced.

Cardiovascular Outcomes Trial#

The CORALreef Outcomes trial (NCT06008756) is enrolling over 19,000 participants to determine whether enlicitide reduces major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, stroke, and coronary revascularization. This trial will provide the definitive evidence for clinical benefit beyond LDL-C lowering.

Special Populations#

Renal Impairment#

The CORALreef Lipids trial stratified randomization by renal function, suggesting that patients with varying degrees of renal impairment were included. Specific subgroup analyses have not been publicly detailed.

Hepatic Impairment#

No dedicated hepatic impairment study data have been published. As a macrocyclic peptide, enlicitide's metabolism may differ from small molecules and antibodies. Liver function monitoring is recommended.

Elderly Patients#

Older adults were included in the CORALreef program (ASCVD population). No dose adjustment for age has been recommended.

Pregnancy and Lactation#

No data are available regarding the use of enlicitide during pregnancy or breastfeeding. Cholesterol is essential for fetal development, and LDL-lowering therapy is generally contraindicated during pregnancy. Women of childbearing potential should discuss family planning with their healthcare provider.

Statin-Intolerant Patients#

The CORALreef program included patients with documented statin intolerance. Enlicitide's mechanism (PCSK9 inhibition) is independent of the mevalonate pathway affected by statins, and PCSK9 inhibition is not associated with myopathy. Specific subgroup results in statin-intolerant patients have not been separately published.

Medical Disclaimer#

The information provided on this page is for educational and research purposes only. It is not intended to serve as medical advice, diagnosis, or treatment recommendation. Enlicitide is an investigational compound not approved for any use. Clinical decisions about lipid-lowering therapy should be made in consultation with a qualified cardiologist or lipid specialist who can consider individual cardiovascular risk factors, existing therapy, and treatment goals.

Related Reading#

• Enlicitide overview and research guide
• Enlicitide side effects profile
• Enlicitide research evidence